(NYSE: PEN) Penumbra's forecast annual revenue growth rate of 9.7% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 6.21%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.3%.
Penumbra's revenue in 2026 is $1,560,334,000.On average, 13 Wall Street analysts forecast PEN's revenue for 2026 to be $63,535,988,620, with the lowest PEN revenue forecast at $60,737,567,285, and the highest PEN revenue forecast at $66,965,040,115. On average, 12 Wall Street analysts forecast PEN's revenue for 2027 to be $72,088,910,165, with the lowest PEN revenue forecast at $68,265,714,820, and the highest PEN revenue forecast at $76,109,177,435.
In 2028, PEN is forecast to generate $81,311,876,255 in revenue, with the lowest revenue forecast at $75,399,718,505 and the highest revenue forecast at $86,396,331,920.